Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Allovectin-7 versus dacarbazine or temozolomide in recurrent metastatic melanoma
NL-OMON31643Phase 3Active, not recruiting
- Sponsor
- Vical Incorporated
- Start
- Apr 2009
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allovectin-7 in melanoma (2 arms), sponsored by Vical Incorporated. Primary endpoint: Overall response rate. Started Apr 2009; status: active, not recruiting.
02
Drugs
allovectin-7
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON31643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31643.